Evogene (EVGN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Evogene (EVGN) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.05 of bullish evidence against -0.42 bearish.

Evogene last closed at $0.38, -5.00% on the session.

Against the IVW growth benchmark the position is -5.80% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for EVGN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Evogene in the 99th percentile on return on equity, where 100 is best.

Evogene is classified under Health Care / Biotechnology, with a market capitalisation of $7.19M.

StockMap tracks Evogene as the 363rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Evogene ranks 346th of 381 in the group, against a group median of -0.08.